Medscape is available in 5 Language Editions – Choose your Edition here.


Pediatric Asplenia Treatment & Management

  • Author: Mudra Kumar, MD, MRCP, FAAP; Chief Editor: Harumi Jyonouchi, MD  more...
Updated: Nov 11, 2014

Medical Care

Once the diagnosis of anatomic or functional asplenia is confirmed, aggressive management is the key to decreasing the morbidity and mortality associated with this condition. Newborn diagnosis of sickle cell disease is essential because the first manifestation of the hemoglobinopathy in these infants may be an asplenia-related fatal bacteremia. Any episode of fever or signs of infection should be promptly and aggressively treated.

Medical care involves 4 key components: antibiotic prophylaxis, appropriate immunization, aggressive management of suspected infection, and parent education.

  • Antibiotic prophylaxis
    • Antibiotic prophylaxis should be initiated immediately upon the diagnosis of asplenia because these patients are at significant risk of pneumococcal infections. For children younger than 2 years, oral penicillin V may be given twice a day. Amoxicillin has also been recommended as an appropriate prophylactic antibiotic. Erythromycin is an alternate choice in patients who are allergic to penicillin.
    • In general, antimicrobial prophylaxis should be considered for all children with asplenia or splenic dysfunction until age 5 years and for at least 1 year after surgical splenectomy. Some experts recommend continuing prophylaxis into adulthood, particularly for high-risk patients.
    • Numerous controversies surround when to discontinue antimicrobial prophylaxis in asplenia and hyposplenia (or if it should be discontinued at all). Arguments for cessation of prophylaxis include poor patient compliance and the development of resistant bacterial strains in patients on daily antibiotics. Those in favor of lifelong prophylaxis cite case reports of overwhelming postsplenectomy sepsis that occurs years after removal of the spleen. Currently, most guidelines leave the option open to continue lifelong prophylaxis based on the clinical circumstances of the individual patient.
  • Immunization
    • All patients should receive all standard childhood and adolescent immunizations at the recommended age. Most importantly, vaccinations against encapsulated organisms, including pneumococcal conjugate and/or polysaccharide, H influenzae type b conjugate, and meningococcal conjugate and/or polysaccharide vaccines, should be administered on the standard schedule.
    • Most of the pediatric pneumococcal bacteremias in the United States are caused by the 13 serotypes covered in the conjugate vaccine: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The conjugate vaccine has been effective in dramatically reducing the occurrence of invasive pneumococcal disease. In children younger than 2 years, the incidence of all invasive pneumococcal infections has decreased by 80% after conjugate vaccine was recommended in the routine childhood immunization schedule. Infections caused by vaccine and vaccine-related serotypes have decreased by 90% in older children and adults.
    • The immunization schedule for pneumococcal conjugate vaccine (PCV13) consists of a primary series of 4 doses (0.5 mL each) at age 2, 4, 6, and 12-15 months. Catch-up immunization schedules are published regarding appropriate dosing schedules for children aged 5 years or younger.
    • The pneumococcal polysaccharide vaccine against 23 serotypes (PPV23) should be given after age 24 months for supplemental protection. A booster dose of PPV23 is appropriate 3-5 years after the first dose. An update from the Advisory Committee on Immunization Practices (ACIP) recommends that for children aged 6-18 years with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants who have not previously received 13-valent pneumococcal conjugate vaccine (PCV13), PCV13 should be administered regardless of whether they received the 7-valent pneumococcal conjugate vaccine (PCV7) or the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
    • Patients should also receive quadrivalent meningococcal vaccine. Four licensed meningococcal vaccines are available in the United States against serotypes A, C, Y, and W-135. Two of these are meningococcal conjugate vaccines (MCV4) and are recommended for infants and toddlers under the age of 2 years who are at an increased risk of invasive meningococcal disease. MCV4 is indicated routinely for all children aged 11-12 years, with a booster given 5 years after the initial vaccine. The availability of a serogroup B vaccine would improve impact and cost-effectiveness of a routine infant meningococcal vaccine program. Patients who were previously vaccinated at age 7 years or older should be revaccinated 5 years after their previous meningococcal vaccine. Patients who were previously vaccinated at age 2-6 years should be revaccinated 3 years after their previous meningococcal vaccine. Although no specific guidelines exist, patients with asplenia should continue to be re-evaluated andrevaccinatedat5-yearintervals.
    • The ACIP and the American Academy of Pediatrics updated the recommendations for the use of quadrivalent (serogroups A, C, W-135, and Y) meningococcal conjugate vaccines (Menactra [Sanofi Pasteur, Swiftwater, PA] and Menveo [Novartis, Basel, Switzerland]) in adolescents and in people at persistent high risk of meningococcal disease.
    • A 2-dose primary series should be administered 2 months apart for those who are at increased risk of invasive meningococcal disease because of persistent complement component (eg, C5-C9, properdin, factor H, or factor D) deficiency (age 9 mo to 54 y) or functional or anatomic asplenia (age 2-54 y) and for adolescents with HIV infection. A booster dose should be given 3 years after the primary series, if the primary 2-dose series was given from age 2-6 years and every 5 years for persons whose 2-dose primary series or booster dose was given at age 7 years or older who are at risk of invasive meningococcal disease because of persistent component (eg, C5-C9, properdin, factor H, or factor D) deficiency or functional or anatomic asplenia.[8]
    • The recommended vaccination schedule for H influenzae type b is a primary series of 3 doses given at age 2, 4, and 6 months or 2 doses given at age 2 and 4 months, depending on the particular conjugate vaccine product administered. A booster dose at age 12 months is recommended for all vaccine products. Children who are undergoing scheduled splenectomy after completion of their primary series and booster dose may benefit from an additional dose of conjugate vaccine at least 7-10 days before surgery. Catch-up immunization schedules regarding H influenzae type b vaccine are published. Patients 5 years or older who never received Hib immunization should receive 1 dose. H influenza type b conjugate vaccine may provide long-term protection to asplenic individuals and should be administered regardless of previous vaccinations and time from splenectomy, even if antibody evaluation is not available.[2, 3]
    • Yearly influenza vaccine is also recommended to minimize the likelihood of secondary bacterial infections.
    • Children 2 years of age or older undergoing elective splenectomy should receive 1 or both pneumococcal vaccines and the meningococcal vaccine at least 2 weeks prior to surgery. Children younger than 2 years should receive PCV13 prior to elective splenectomy. Ensure the Hib vaccination series is completed.
  • Management of suspected infection
    • The risk of serious bacterial infection is always present in these patients. Many patients have trivial symptoms yet rapidly develop fulminant sepsis and death within hours.
    • All patients with impaired splenic function with suspected infection must be urgently and promptly evaluated. Obtain blood, urine, and, if indicated, cerebrospinal fluid (CSF) cultures. Initiate broad-spectrum intravenous antibiotics effective against S pneumoniae, H influenzae type b, and N meningitidis. Because of the fulminant nature of infections with these agents, intravenous antibiotics need to be initiated before bacteriological results are available. Second-generation or third-generation cephalosporins may be the initial choices. If multiple-drug resistance is a concern, vancomycin should be added to the regimen. In addition, many patients require supportive care with intravenous fluids, volume expanders, and pressor support.
    • Because of the potential rapid progression of a serious bacterial infection, some experts recommend that asplenic patients have access to "stand-by" antibiotics, which can be initiated at the first sign of infection (fever, chills, or malaise). That the initiation of "stand-by" antibiotics is not a substitute for seeking immediate medical attention at the onset of an illness cannot be overemphasized.
    • Patients with asplenia are at an increased risk of sepsis, shock, and meningitis secondary to Capnocytophaga canimorsus resulting from dog, cat, or rodent bites. The diagnosis may be made by means of Gram staining of the buffy coat, blood, and CSF cultures. Early treatment with penicillin is the therapy of choice, but cephalosporins, clindamycin, and erythromycin may also be used.
  • Parent education
    • The most important component in the treatment of these patients is parent education. Risks must be explained to all caretakers because they are an integral part of the management team. Seeking medical advice at the first sign of illness is crucial.
    • Ongoing education must become a part of each physician-parent encounter so that the parents remain vigilant, which allows potentially serious infections to be identified early and managed aggressively. The child should wear a Medic Alert bracelet that reads "Asplenia" or "No Spleen." Written instructions should be given to the parents in a form that they can keep with them. For example, they can be given a wallet-sized card with the child's diagnosis and concise guidelines for early treatment and intervention.

Surgical Care

See the list below:

  • Elective splenectomy for conditions such as hemolytic anemia are strongly discouraged before age 6 years and should be delayed as long as possible.
  • Options to splenectomy should be considered when appropriate. These include partial splenectomy or embolization, conservative management of splenic trauma, and autotransplantation.
  • To the author's knowledge, no data support the routine use of prophylactic antibiotics in the perioperative period.
  • When surgical splenectomy is imminent, administration of pneumococcal, H influenzae type b, and meningococcal vaccines at least 2 weeks before splenectomy, if possible, is appropriate. If the immunizations are not received prior to surgery, some recommend immunization 14-21 days postsurgery because of enhanced immune response, compared with immediately postsurgery.
  • Surgical splenectomy in patients with immunodeficiency should be avoided because of increased risk of invasive bacterial infections.


See the list below:

  • No restrictions on activities are usually advised.
  • Infections with H influenzae type b and pneumococcal and meningococcal bacteria are known to be increased among immunologically competent children and adults in daycare centers, college dormitories, military barracks, and other crowded facilities. Therefore, the risks of these situations should be explained to patients and their families.
Contributor Information and Disclosures

Mudra Kumar, MD, MRCP, FAAP Professor of Pediatrics, Course Director, Course 6 MSII, Preclerkship Director, Clinical Integration, Department of Pediatrics, University of South Florida Morsani College of Medicine

Mudra Kumar, MD, MRCP, FAAP is a member of the following medical societies: American Academy of Pediatrics, American Society of Hematology, American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.


Cecilia P Mikita, MD, MPH Associate Program Director, Allergy-Immunology Fellowship, Associate Professor of Pediatrics and Medicine, Uniformed Services University of the Health Sciences; Staff Allergist/Immunologist, Walter Reed National Military Medical Center

Cecilia P Mikita, MD, MPH is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American College of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Joseph C Turbyville, MD Allergist-Immunologist, Family Allergy and Asthma

Joseph C Turbyville, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American College of Allergy, Asthma and Immunology

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Chief Editor

Harumi Jyonouchi, MD Faculty, Division of Allergy/Immunology and Infectious Diseases, Department of Pediatrics, Saint Peter's University Hospital

Harumi Jyonouchi, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association of Immunologists, American Medical Association, Clinical Immunology Society, New York Academy of Sciences, Society for Experimental Biology and Medicine, Society for Pediatric Research, Society for Mucosal Immunology

Disclosure: Nothing to disclose.


John Wilson Georgitis, MD Consulting Staff, Lafayette Allergy Services

John Wilson Georgitis, MD is a member of the following medical societies: American Academy of Allergy Asthma and Immunology, American Academy of Pediatrics, American Association for the Advancement of Science, American College of Chest Physicians, American Lung Association, American Medical Writers Association, and American Thoracic Society

Disclosure: Nothing to disclose.

Francine Gross, MD Consulting Staff, Department of Pediatrics, Winter Haven Hospital

Disclosure: Nothing to disclose.


The authors wish to thank Oswaldo Castro, MD, for his assistance in reviewing this manuscript and providing expertise with regards to management of patients with sickle cell disease and asplenia.

  1. Paterson A, Frush DP, Donnelly LF, Foss JN, O'Hara SM, Bisset GS 3rd. A pattern-oriented approach to splenic imaging in infants and children. Radiographics. 1999 Nov-Dec. 19(6):1465-85. [Medline].

  2. Mikoluc B, Michalkiewicz J, Motkowski R, Smolka D, Pietrucha B, Piotrowska-Jastrzebska J, et al. Neutrophil phenotypic characteristics in children with congenital asplenia and splenectomized for hereditary spherocytosis. Immunol Invest. 2012. 41(1):61-74. [Medline].

  3. Mikoluc B, Motkowski R, Käyhty H, Heropolitanska-Pliszka E, Pietrucha B, Bernatowska E. Antibody response to Haemophilus influenzae type-b conjugate vaccine in children and young adults with congenital asplenia or after undergoing splenectomy. Eur J Clin Microbiol Infect Dis. 2012 May. 31(5):805-9. [Medline]. [Full Text].

  4. Motkowski R, Michalkiewicz J, Mikoluc B, Smolka-Afifi D, Pietrucha B, Kubiszewska I, et al. Peripheral blood T lymphocyte subsets in children with congenital asplenia. Hum Immunol. 2012 Nov. 73(11):1091-7. [Medline].

  5. Morgan TL, Tomich EB. Overwhelming post-splenectomy infection (OPSI): a case report and review of the literature. J Emerg Med. 2012 Oct. 43(4):758-63. [Medline].

  6. Uchida Y, Matsubara K, Wada T, Oishi K, Morio T, Takada H, et al. Recurrent bacterial meningitis by three different pathogens in an isolated asplenic child. J Infect Chemother. 2012 Aug. 18(4):576-80. [Medline].

  7. Konda S, Zell D, Milikowski C, Alonso-Llamazares J. Purpura fulminans associated with Streptococcus pneumoniae septicemia in an asplenic pediatric patient. Actas Dermosifiliogr. 2013 Sep. 104(7):623-7. [Medline].

  8. Committee on Infectious Diseases. Meningococcal conjugate vaccines policy update: booster dose recommendations. Pediatrics. 2011 Dec. 128(6):1213-8. [Medline].

  9. Angelski CL, McKay E, Blackie B. A case of functional asplenia and pneumococcal sepsis. Pediatr Emerg Care. 2011 Jul. 27(7):639-41. [Medline].

  10. Casey B, Devoto M, Jones KL, Ballabio A. Mapping a gene for familial situs abnormalities to human chromosome Xq24-q27.1. Nat Genet. 1993 Dec. 5(4):403-7. [Medline].

  11. Chellapandian D, Schneider A. Anatomical asplenia in cat eye syndrome: an expansion of the disease spectrum. Case Rep Pediatr. 2013. 2013:218124. [Medline]. [Full Text].

  12. Committee on Infectious Diseases American Academy of Pediatrics. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th Ed. 2006.

  13. Couturier AP, Dahl K. Bordetella holmesii endocarditis: case report and review of literature. Pediatr Infect Dis J. 2014 Jun. 33(6):661-4. [Medline].

  14. Elsayes KM, Narra VR, Mukundan G, et al. MR imaging of the spleen: spectrum of abnormalities. Radiographics. 2005. Jul-Aug;25(4):967-82. [Medline]. [Full Text].

  15. Escobar-Diaz MC, Friedman K, Salem Y, Marx GR, Kalish BT, Lafranchi T, et al. Perinatal and infant outcomes of prenatal diagnosis of heterotaxy syndrome (asplenia and polysplenia). Am J Cardiol. 2014 Aug 15. 114(4):612-7. [Medline].

  16. Fremont RD, Rice TW. Splenosis: a review. South Med J. 2007 Jun. 100(6):589-93. [Medline].

  17. Garson A, Bricker JT, McNamara DG. The Science and Practice of Pediatric Cardiology. 1990. Vol 3: 1288-97.

  18. Gaschignard J, Levy C, Chrabieh M, Boisson B, Bost-Bru C, Dauger S, et al. Invasive pneumococcal disease in children can reveal a primary immunodeficiency. Clin Infect Dis. 2014 Jul 15. 59(2):244-51. [Medline]. [Full Text].

  19. Gill DG, Kara M, Moore L. Archives of diseases in childhood. 1991. Vol 66: 1366.

  20. Gonzalez P, Humeres P, Arroyo A. Liver uptake with phytate colloid in normal subjects and patients with cirrhosis: a possible alternative to extrahepatic measurements. J Nucl Med. 1991 Jul. 32(7):1467-8. [Medline].

  21. Gorg C, Eickhorn M, Zugmaier G. The small spleen: sonographic patterns of functional hyposplenia or asplenia. J Clin Ultrasound. 2003. Mar-Apr;31(3):152-5. [Medline].

  22. Harrod VL, Howard TA, Zimmerman SA, Dertinger SD, Ware RE. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol. 2007 Feb. 35(2):179-83. [Medline].

  23. Katcher AL. Familial asplenia, other malformations, and sudden death. Pediatrics. 1980. 65(3):633-635. [Medline].

  24. Kevy SV, Tefft M, Vawier GF, Rosen FS. Hereditary splenic hypoplasia. Pediatrics. 1968 Nov. 42(5):752-7. [Medline].

  25. Kim SJ. Heterotaxy syndrome. Korean Circ J. 2011 May. 41(5):227-32. [Medline]. [Full Text].

  26. Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood. 1995 Apr 15. 85(8):2238-44. [Medline].

  27. Leahy RT, Philip RK, Gibbons RJ, et al. Asplenia in ATR-X Syndrome: a second report. Am J Med Genet A. 2005. 15;139 (1):37-9. [Medline].

  28. Lin XZ, Chang TM, Tsai HM, et al. Liver, spleen and tumor volume measured by personal computer. Hepatogastroenterology. 1999 Mar-Apr. 46(26):838-42. [Medline].

  29. Lindor NM, Smithson WA, Ahumada CA, et al. Asplenia in two father-son pairs. Am J Med Genet. 1995 Mar 13. 56(1):10-1. [Medline].

  30. Long WA. Ivemark syndrome (cardiosplenic or heterotaxy syndrome). Fetal and Neonatal Cardiology. 1990. 616-19.

  31. Mahlaoui N, Minard-Colin V, Picard C, Bolze A, Ku CL, Tournilhac O, et al. Isolated congenital asplenia: a French nationwide retrospective survey of 20 cases. J Pediatr. 2011 Jan. 158(1):142-8, 148.e1. [Medline].

  32. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005 Aug. 5(8):606-16. [Medline].

  33. Melles DC, de Marie S. Prevention of infections in hyposplenic and asplenic patients: an update. Neth J Med. 2004 Feb. 62(2):45-52. [Medline].

  34. Moller JH, Neal WA. Congenital cardiac anomalies. Fetal, Neonatal, and Infant Cardiac Disease. 1990. 767-71.

  35. Morgan MS. Prophylaxis should be considered even for trivial animal bites. BMJ. 1997 May 10. 314(7091):1413. [Medline].

  36. Panagopoulos MI, Saint Jean M, Brun D, Guiso N, Bekal S, Ovetchkine P, et al. Bordetella holmesii bacteremia in asplenic children: report of four cases initially misidentified as Acinetobacter lwoffii. J Clin Microbiol. 2010 Oct. 48(10):3762-4. [Medline]. [Full Text].

  37. Pearson HA. The spleen and disturbances of splenic function. Hematology. 1993. 2:1058-9.

  38. Pollak U, Bar-Sever Z, Hoffer V, Marcus N, Scheuerman O, Garty BZ. Asplenia and functional hyposplenism in autoimmune polyglandular syndrome type 1. Eur J Pediatr. 2009 Feb. 168(2):233-5. [Medline].

  39. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am. 2007 Sep. 21(3):697-710, viii-ix. [Medline].

  40. Price VE, Blanchette VS, Ford-Jones EL. The prevention and management of infections in children with asplenia or hyposplenia. Infect Dis Clin North Am. 2007 Sep. 21(3):697-710, viii-ix. [Medline].

  41. Price VE, Dutta S, Blanchette VS, et al. The prevention and treatment of bacterial infections in children with asplenia or hyposplenia: practice considerations at the Hospital for Sick Children, Toronto. Pediatr Blood Cancer. 2006. May 1;46(5):597-603. [Medline].

  42. Rose V, Izukawa T, Moes CA. Syndromes of asplenia and polysplenia. A review of cardiac and non- cardiac malformations in 60 cases with special reference to diagnosis and prognosis. Br Heart J. 1975 Aug. 37(8):840-52. [Medline].

  43. Stiehm ER. Immunodeficiency disorders. Immunologic Disorders in Infants and Children. 1996. 4th ed: 326-327.

  44. Strouse PJ, Haller JO, Berdon WE, Rosovsky MA, Bellah RD, Barr Jr M. Horseshoe adrenal gland in association with asplenia: presentation of six new cases and review of the literature. Pediatr Radiol. 2002 Nov. 32(11):778-82. [Medline].

  45. Tham KT, Teague MW, Howard CA, Chen SY. A simple splenic reticuloendothelial function test: counting erythrocytes with argyrophilic inclusions. Am J Clin Pathol. 1996 May. 105(5):548-52. [Medline].

  46. Tribioli C, Lufkin T. The murine Bapx1 homeobox gene plays a critical role in embryonic development of the axial skeleton and spleen. Development. 1999 Dec. 126(24):5699-711. [Medline].

  47. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb Mortal Wkly Rep. 2009 Sep 25. 58(37):1042-3. [Medline].

  48. Updated recommendations on the use of meningococcal vaccines. Pediatrics. 2014 Aug. 134(2):400-3. [Medline].

  49. US Preventive Services Task Force. Screening for sickle cell disease in newborns: recommendation statement. Am Fam Physician. 2008 May 1. 77(9):1300-2. [Medline].

  50. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013 Jun 28. 62(25):521-4. [Medline].

  51. Waldman JD, Rosenthal A, Smith AL, et al. Sepsis and congenital asplenia. J Pediatr. 1977 Apr. 90(4):555-9. [Medline].

  52. Wang JK, Hsieh KH. Immunologic study of the asplenia syndrome. Pediatr Infect Dis J. 1991 Nov. 10(11):819-22. [Medline].

  53. Wolla CD, Hlavacek AM, Schoepf UJ, Bucher AM, Chowdhury S. Cardiovascular manifestations of heterotaxy and related situs abnormalities assessed with CT angiography. J Cardiovasc Comput Tomogr. 2013 Nov-Dec. 7(6):408-16. [Medline]. [Full Text].

  54. Wong T, Yeung J, Hildebrand KJ, Junker AK, Turvey SE. Human primary immunodeficiencies causing defects in innate immunity. Curr Opin Allergy Clin Immunol. 2013 Dec. 13(6):607-13. [Medline].

  55. Woods CR. Prevention of meningococcal infections in the first 2 years of life. Pediatr Ann. 2013 Aug. 42(8):164-71. [Medline].

  56. Yamamura K, Joo K, Ohga S, Nagata H, Ikeda K, Muneuchi J, et al. Thrombocytosis in asplenia syndrome with congenital heart disease: a previously unrecognized risk factor for thromboembolism. Int J Cardiol. 2013 Sep 1. 167(5):2259-63. [Medline].

Peripheral blood smear shows Howell-Jolly (HJ) bodies in RBCs.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.